Inozyme Pharma Stock Probability Of Bankruptcy
| INZY Stock | USD 2.96 0.02 0.67% |
Inozyme | Probability Of Bankruptcy |
Inozyme Pharma Company probability of bankruptcy Analysis
Inozyme Pharma's Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current Inozyme Pharma Probability Of Bankruptcy | Over 51% |
Most of Inozyme Pharma's fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Inozyme Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of Inozyme Pharma probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Inozyme Pharma odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Inozyme Pharma financial health.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Inozyme Pharma. If investors know Inozyme will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Inozyme Pharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.55) | Return On Assets (0.36) | Return On Equity (0.79) |
The market value of Inozyme Pharma is measured differently than its book value, which is the value of Inozyme that is recorded on the company's balance sheet. Investors also form their own opinion of Inozyme Pharma's value that differs from its market value or its book value, called intrinsic value, which is Inozyme Pharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Inozyme Pharma's market value can be influenced by many factors that don't directly affect Inozyme Pharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Inozyme Pharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Inozyme Pharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Inozyme Pharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Inozyme Probability Of Bankruptcy Driver Correlations
Understanding the fundamental principles of building solid financial models for Inozyme Pharma is extremely important. It helps to project a fair market value of Inozyme Stock properly, considering its historical fundamentals such as Probability Of Bankruptcy. Since Inozyme Pharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Inozyme Pharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Inozyme Pharma's interrelated accounts and indicators.
Click cells to compare fundamentals
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
| Competition |
Based on the latest financial disclosure, Inozyme Pharma has a Probability Of Bankruptcy of 51%. This is 17.81% higher than that of the Biotechnology sector and 7.0% lower than that of the Health Care industry. The probability of bankruptcy for all United States stocks is 28.04% lower than that of the firm.
Inozyme Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Inozyme Pharma's direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Inozyme Pharma could also be used in its relative valuation, which is a method of valuing Inozyme Pharma by comparing valuation metrics of similar companies.Inozyme Pharma is currently under evaluation in probability of bankruptcy category among its peers.
Inozyme Pharma Main Bankruptcy Drivers
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Return On Assets | (0.39) | (0.33) | (0.46) | (0.47) | (0.35) | (0.37) | |
| Net Debt | (31.6M) | (158.6M) | (19.9M) | (26.1M) | 12.0M | 12.6M | |
| Total Current Liabilities | 3.2M | 10.0M | 11.6M | 14.7M | 14.7M | 10.4M | |
| Non Current Liabilities Total | 77.9M | 1.3M | 2.6M | 6.1M | 45.7M | 25.2M | |
| Total Assets | 47.9M | 169.4M | 123.5M | 139.2M | 200.8M | 132.8M | |
| Total Current Assets | 47.5M | 151.0M | 115.3M | 131.4M | 196.3M | 125.5M | |
| Total Cash From Operating Activities | (18.8M) | (36.0M) | (48.2M) | (57.8M) | (70.7M) | (67.1M) |
Inozyme Pharma ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Inozyme Pharma's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Inozyme Pharma's managers, analysts, and investors.Environmental | Governance | Social |
Inozyme Fundamentals
| Return On Equity | -0.79 | ||||
| Return On Asset | -0.36 | ||||
| Current Valuation | 89.92 M | ||||
| Shares Outstanding | 64.24 M | ||||
| Shares Owned By Insiders | 0.50 % | ||||
| Shares Owned By Institutions | 96.67 % | ||||
| Number Of Shares Shorted | 3.31 M | ||||
| Price To Book | 2.11 X | ||||
| EBITDA | (74.81 M) | ||||
| Net Income | (71.17 M) | ||||
| Cash And Equivalents | 151.48 M | ||||
| Cash Per Share | 3.77 X | ||||
| Total Debt | 46.59 M | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 14.54 X | ||||
| Book Value Per Share | 1.29 X | ||||
| Cash Flow From Operations | (70.67 M) | ||||
| Short Ratio | 7.59 X | ||||
| Earnings Per Share | (1.55) X | ||||
| Price To Earnings To Growth | (0.06) X | ||||
| Target Price | 18.75 | ||||
| Number Of Employees | 59 | ||||
| Beta | 1.54 | ||||
| Market Capitalization | 191.44 M | ||||
| Total Asset | 200.85 M | ||||
| Retained Earnings | (285.93 M) | ||||
| Working Capital | 181.56 M | ||||
| Net Asset | 200.85 M |
About Inozyme Pharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Inozyme Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Inozyme Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Inozyme Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Inozyme Stock Analysis
When running Inozyme Pharma's price analysis, check to measure Inozyme Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Inozyme Pharma is operating at the current time. Most of Inozyme Pharma's value examination focuses on studying past and present price action to predict the probability of Inozyme Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Inozyme Pharma's price. Additionally, you may evaluate how the addition of Inozyme Pharma to your portfolios can decrease your overall portfolio volatility.